Chrysalyne D. Schmults, MD, MSCE, is an associate professor of dermatology at Harvard Medical School. She received her medical degree from Yale School of Medicine in New Haven, CT, completed her residency at New York University School of Medicine in New York, NY, and her fellowship was completed at Skin Laser and Surgery Specialist of NY and NJ in New York, NY.
For 4 years, Dr Schmults was a part of the faculty at the University of Pennsylvania before becoming the director of the Brigham and Women’s Hospital (BWH) Mohs and Dermatologic Surgery Center in Boston, MA. She founded the Dana Farber Cancer Institute High-Risk Skin Cancer Clinic that cares for patients with multiple skin cancers, severe sun damage, or tumors at high risk for recurrence. The clinic has become a referral center for patients with locally advanced and metastatic basal and squamous cell carcinoma (BCC and SCC, respectively) in need of advanced multidisciplinary care and clinical trials. The clinic is one of only a handful worldwide that is dedicated to this patient population.
Dr Schmults has developed new staging systems for SCC and BCC, which for the first time identified the subset of patients in need of studies of staging and adjuvant treatment. She was a member of the American Joint Committee on Cancer (AJCC) 8th edition SCC task force, which was informed by her BWH SCC staging system, and is the editor of the first textbook on high-risk SCC. She is currently the chair of the non-melanoma panel of the National Comprehensive Cancer Network (NCCN) which develops guidelines of care for cancer patients.
Dr Schmults has served on the board of directors of the American College of Mohs Surgeons and the International Society for Dermatologic Surgery, and as president of the International Immunology and Transplant Skin Cancer Collaborative.